{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Complete Response(CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Pathologic partial response (pPR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Progressive disease (PD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"No evidence of disease (NED)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Response to Concurrent Erlotinib, Celecoxib, and Reirradiation according to Response Evaluation Criteria in Solid Tumors - Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions","groups":[{"description":"erlotinib + celecoxib: In this phase I/II study, patients will be treated with daily erlotinib 150 mg and twice-daily celecoxib 200 to 600 mg for 14 days. Re-irradiation with IMRT will start on day 15 and will continue for 5.5 to 6.5 weeks along with erlotinib and celecoxib. After completion of radiation, patients will be given the option of continuing on erlotinib for 2 years or until unacceptable toxicity or disease progression","id":"OG000","title":"Erlotinib + Celecoxib"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"20 months","title":"Clinical Response","type":"SECONDARY","unitOfMeasure":"Participants"}